ProductOverview:

Anewrobustandversatileserum-freemediumformulationforhighandlowdensityNHEK-NormalHumanEpidermalKeratinocytecultures

KGM-Gold™KeratinocyteGrowthMediumisdesignedtosupportbothclonalgrowthandhighdensitykeratinocyteproliferation.ThemediumsupportssuperiorgrowthandmorphologyofkeratinocytesisolatedinKGM-2™(datanotshown),KGM™(datanotshown)andCompetitorA"sMedium(datashownbelow).  

FurThermore,qualitycontrolatLonzarequiresthatkeratinocytespassstrictmorphologicalcriteriaspecifyingtheminimalpresenceofenlargedandvacuolatedcells,enablingLonzakeratinocytestobeusedbytheresearcherfor≥15PopulationDoublings. 

Adultandneonatalkeratinocytesarealsoavailable. 

RecommendedSubculturingReagents: ReagentPack^TMSubcultureReagents

Inaside-by-sidecomparisonwithamajorcompetitor’sformulation,culturesmaintainedinKGM-Gold™KeratinocyteGrowthMediumhadamorehomogeneousphenotypeconsistingofsmallrefractilecellswithminimalenlargementandvacuolization.TheABIlityofKGM-Gold™MediumtopromotethehealthofNHEK-NormalHumanEpidermalKeratinocytecellspositivelyinfluenceskeratinocyteLifespan.

Figure4A: GrowthofLonza’sadultkeratinocytesgrowninKGM-Gold™GrowthMediumcomparedtoCompetitorA’sadultkeratinocytesintheirmedium.

Lonza’sadultkeratinocytesgrowninKGM-Gold™outperformedcompetitorA’sadultkeratinocytesgrownintheirownmediumingrowthrate(Figure-4A),andmorphology(Figure-4B)uptoandevenbeyond15populationdoublings.ThisdatashowsthatalthoughcompetitorAclaimsextendedlifespanoftheirkeratinocytesintheirownmedium,thehealthandmorphologyoftheseadultkeratinocytesispoorbeyond13-15populationdoublings,renderingtheculturesunusableforfurtherexperimentation.

Figure4B: MorphologyofLonza’sadultkeratinocytesgrowninKGM-Gold™GrowthMediumcomparedtoCompetitorA’sadultkeratinocytesintheirmedium.

Lonza"sAdultKeratinocytes in KGM-Gold™Medium	CompetiorA"sAdultKeratinocytes inTheirMedium
Day13,15TPD	Day25,17TPD		Findmoredatainourwhitepaper:"ASerum-freeMediumforNormalHumanEpidermalKeratinocytes(NHEK)"         Registertodownload
Day20,19TPD	Day32,19TPD

ThegrowthperformanceandlongevityofCompetitorA"sadultkeratinocytesgrowninCompetitorA"sMediumwerecomparedwithLonza’sadultkeratinocytesgrowninKGM-Gold™GrowthMedium. AlthoughCompetitorAclaims≥25totalpopulationdoublingsfortheiradultkeratinocytes,actualresultsshowthatthislotbarelyobtained19PD. NotethepresenceofseveralenlargedcellsinPassage2inCompetitor’sMedium. Attheendofpassage4(15PD)Lonza’sadultkeratinocytesconsistofmostlysmallproliferativecells.

New!PurchaseourAdultKeratinocyteCellCultureKit(catalogno.192627B)andgetadiscountedpriceoncellsandmedia. Thekitconsistsofacryopreservedampuleofadultkeratinocytes(catalogno.192627)andKGM™-GoldBulletKit™GrowthMedia(catalogno.192060)

龙沙生物技术有限公司于2019年05月10日成立。法定代表人David Johann Wach，公司经营范围包括：生物技术开发服务（我国稀有和特有的珍贵优良品种，国家保护的原产于我国的野生动、植物资源开发除外）;生物技术推广服务（我国稀有和特有的珍贵优良品种，国家保护的原产于我国的野生动、植物资源开发除外）;生物技术咨询、交流服务（我国稀有和特有的珍贵优良品种，国家保护的原产于我国的野生动、植物资源开发除外）;生物技术转让服务（我国稀有和特有的珍贵优良品种，国家保护的原产于我国的野生动、植物资源开发除外）;医学研究和试验发展（人体干细胞、基因诊断与治疗技术除外）;药品研发（人体干细胞、基因诊断与治疗技术除外）;货物进出口(涉及外资准入特别管理规定和许可审批的商品除外);技术进出口;贸易代理;商品批发贸易（涉及外资准入特别管理规定和许可审批的商品除外）;生物药品制造;化学药品原料药制造;化学药品制剂制造等。